Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies

Abstract

Aims

We aimed to clarify the associations of high-density lipoprotein cholesterol (HDL-C) subclasses with incident coronary heart disease (CHD) in two large primary prevention cohorts.

Methods

We measured cholesterol at baseline from the two major HDL subfractions (larger, more buoyant HDL₂ and smaller, denser HDL₃) separated by density gradient ultracentrifugation in 4114 (mean age 53.8 years; 64% female) African American participants from the Jackson Heart Study and 818 (mean age 57.3 years, 52% female) predominantly Caucasian participants from the Framingham Offspring Cohort Study. Multivariable adjusted hazard ratios (HRs) for HDL-C and its subclasses were derived from Cox proportional hazards regression models to estimate associations with incident CHD events including myocardial infarction, CHD death, and revascularization. Analyses were performed for each cohort separately and as a combined population.

Results

In models adjusted for cardiovascular risk factors for the combined population, HDL₃-C (HR 0.76 per SD increase; 95% confidence interval (CI), 0.62–0.94; p = 0.01), rather than HDL₂-C (HR 0.88 per SD; 95% CI, 0.72–1.09; p = 0.24) drove the inverse association of HDL-C (HR 0.79 per SD; 95% CI, 0.64–0.98; p = 0.03) with CHD. Similar associations were seen in multivariable analyses within each cohort including after adjusting for apolipoprotein A1 in the Jackson Heart Study.

Conclusion

Smaller, denser HDL₃-C levels are primarily responsible for the inverse association between HDL-C and incident CHD in this diverse group of primary prevention subjects. These findings have important implications ranging from considerations of HDL biology to interpretations of clinical trials utilizing HDL-C therapeutics.

Keywords

High-density lipoprotein cholesterol coronary heart disease primary prevention

Get full access to this article

View all access options for this article.

References

Gofman

Young

Tandy

. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966; 34: 679–697.

Gordon

Probstfield

Garrison

. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.

Cui

Jousilahti

. Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease. Eur J Prev Cardiol 2013; 20: 89–97.

Goff

DC Lloyd-Jones

Bennett

. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 Pt B): 2935–2959.

Ballantyne

Herd

Ferlic

. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736–743.

Cui

Watson

Girman

. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol 2009; 104: 829–834.

Goldenberg

Goldbourt

Boyko

. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006; 97: 466–471.

Nicholls

Tuzcu

Sipahi

. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499–508.

Barter

Caulfield

Eriksson

. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.

10.

Group

HTC

. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279–1291.

11.

Investigators

A-H

Boden

Probstfield

. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255–2267.

12.

Schwartz

Olsson

Abt

. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089–2099.

13.

Heinecke

. HDL and cardiovascular-disease risk – time for a new approach? N Engl J Med 2011; 364: 170–171.

14.

Shah

. Jekyll and Hyde of HDL: A lipoprotein with a split personality. Eur Heart J 2013; 34: 3531–3534.

15.

Khera

Cuchel

de la Llera-Moya

. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127–135.

16.

Movva

Rader

. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54: 788–800.

17.

Vickers

Remaley

. HDL and cholesterol: Life after the divorce? J Lipid Res 2014; 55: 4–12.

18.

Vaisar

Pennathur

Green

. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746–756.

19.

Rosenson

Brewer

HB Davidson

. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905–1919.

20.

Heinecke

. The protein cargo of HDL: Implications for vascular wall biology and therapeutics. J Clin Lipidol 2010; 4: 371–375.

21.

Davidson

Silva

Chantepie

. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870–876.

22.

Salonen

Seppanen

. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84: 129–139.

23.

Lamarche

Moorjani

Cantin

. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098–1105.

24.

Stampfer

Sacks

Salvini

. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373–381.

25.

Sweetnam

Bolton

Yarnell

. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994; 90: 769–774.

26.

Superko

Pendyala

Williams

. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 2012; 6: 496–523.

27.

Taylor

HA Wilson

Jones

. Toward resolution of cardiovascular health disparities in African Americans: Design and methods of the Jackson Heart Study. Ethn Dis 2005; 15: S6–4–17.

28.

Feinleib

Kannel

Garrison

. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975; 4: 518–525.

29.

D’Agostino

RB Vasan

Pencina

. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743–753.

30.

Kulkarni

Marcovina

Krauss

. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res 1997; 38: 2353–2364.

31.

Peer

Steyn

Lombard

. Alarming rise in prevalence of atherogenic dyslipidaemia in the black population of Cape Town: The Cardiovascular Risk in Black South Africans (CRIBSA) study. Eur J Prev Cardiol. Epub ahead of print 23 July 2013. DOI: 10.1177/2047487313497865.

32.

Martin SS, Khokhar AA, May HT, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The lipoprotein investigators collaborative. Eur Heart J. Epub ahead of print 30 June 2014. DOI: 10.1093/eurheartj/ehu264.

33.

Vega

Clark

Tang

. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 1998; 39: 228–232.

34.

Juo

Han

Smith

. Promoter polymorphisms of hepatic lipase gene influence HDL(2) but not HDL(3) in African American men: CARDIA study. J Lipid Res 2001; 42: 258–264.

35.

Camont

Lhomme

Rached

. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013; 33: 2715–2723.

36.

Shepherd

Packard

Patsch

. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858–867.

37.

Brousseau

Schaefer

Wolfe

. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505–1515.

38.

Sorisky

Ooi

Simo

. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis 1987; 67: 181–189.

39.

Chapman

Ginsberg

Amarenco

. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011; 32: 1345–1361.

40.

Group

Ginsberg

Elam

. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–1574.

41.

Akinkuolie

Paynter

Padmanabhan

. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes 2014; 7: 55–63.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.45 MB